Articles with public access mandates - Richard Goldberg MDLearn more
Not available anywhere: 6
Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III …
SR Alberts, DJ Sargent, TC Smyrk, AF Shields, E Chan, RM Goldberg, ...
Journal of Clinical Oncology 28 (18_suppl), CRA3507-CRA3507, 2010
Mandates: US National Institutes of Health
Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147.
RM Goldberg, DJ Sargent, SN Thibodeau, MR Mahoney, AF Shields, ...
Journal of Clinical Oncology 28 (15_suppl), 3508-3508, 2010
Mandates: US National Institutes of Health
Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer
J Wang, J Xiu, Y Baca, F Battaglin, H Arai, N Kawanishi, S Soni, W Zhang, ...
Oncogene 40 (30), 4894-4905, 2021
Mandates: US National Institutes of Health, V Foundation, USA
Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials
C Gallois, Q Shi, JP Meyers, T Iveson, SR Alberts, A De Gramont, ...
Journal of Clinical Oncology 41 (4), 803-815, 2023
Mandates: Cancer Research UK
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from …
SR Alberts, SN Thibodeau, DJ Sargent, MR Mahoney, F Sinicrope, ...
Journal of Clinical Oncology 29 (15_suppl), 3607-3607, 2011
Mandates: US National Institutes of Health
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147.
J Huang, DJ Sargent, MR Mahoney, AF Shields, E Chan, RM Goldberg, ...
Journal of Clinical Oncology 29 (15_suppl), 3522-3522, 2011
Mandates: US National Institutes of Health
Available somewhere: 190
PD-1 blockade in tumors with mismatch-repair deficiency
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ...
New England Journal of Medicine 372 (26), 2509-2520, 2015
Mandates: US National Institutes of Health
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ...
Journal of Clinical Oncology 28 (22), 3617-3622, 2010
Mandates: US National Institutes of Health
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
Mandates: US National Institutes of Health
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872-877, 2009
Mandates: US National Institutes of Health
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
CJ Allegra, G Yothers, MJ O'Connell, S Sharif, NJ Petrelli, LH Colangelo, ...
Journal of Clinical Oncology 29 (1), 11-16, 2011
Mandates: US National Institutes of Health
Platinum neurotoxicity pharmacogenetics
SR McWhinney, RM Goldberg, HL McLeod
Molecular cancer therapeutics 8 (1), 10-16, 2009
Mandates: US National Institutes of Health
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841
J Franko, Q Shi, CD Goldman, BA Pockaj, GD Nelson, RM Goldberg, ...
Journal of Clinical Oncology 30 (3), 263-267, 2012
Mandates: US National Institutes of Health
Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer
R Pearlman, WL Frankel, B Swanson, W Zhao, A Yilmaz, K Miller, ...
JAMA oncology 3 (4), 464-471, 2017
Mandates: US National Institutes of Health
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
SR Alberts, DJ Sargent, S Nair, MR Mahoney, M Mooney, SN Thibodeau, ...
Jama 307 (13), 1383-1393, 2012
Mandates: US National Institutes of Health
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B …
MM Bertagnolli, D Niedzwiecki, CC Compton, HP Hahn, M Hall, B Damas, ...
Journal of clinical Oncology 27 (11), 1814-1821, 2009
Mandates: US National Institutes of Health
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741
HK Sanoff, DJ Sargent, ME Campbell, RF Morton, CS Fuchs, ...
Journal of Clinical Oncology 26 (35), 5721-5727, 2008
Mandates: US National Institutes of Health
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes
FA Sinicrope, Q Shi, TC Smyrk, SN Thibodeau, R Dienstmann, J Guinney, ...
Gastroenterology 148 (1), 88-99, 2015
Mandates: US National Institutes of Health
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a …
J Tabernero, HJ Lenz, S Siena, A Sobrero, A Falcone, M Ychou, ...
The Lancet Oncology 16 (8), 937-948, 2015
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program